Ecer asks for your consent to use your personal data to:
Personalised advertising and content, advertising and content measurement, audience research and services development
Store and/or access information on a device
Your personal data will be processed and information from your device (cookies, unique identifiers, and other device data) may be stored by, accessed by and shared with 135 TCF vendor(s) and 65 ad partner(s), or used specifically by this site or app.
Some vendors may process your personal data on the basis of legitimate interest, which you can object to by do not consent. Contact our platform customer service, you can also withdraw your consent.
COVID-19 and M.pneumoniae IgG Combo Rapid Test,detection of IgG antibodies to SARS-COV-2 and Mycoplasma pneumoniae
Principle
Chromatographic Immunoassay
Format
Cassette
Specimen
WB/S/P
Certificate
CE
Reading Time
10 minutes
Pack
25 T
Storage Temperature
2-30°C
Shelf Life
2 Years
The COVID-19 and M.pneumoniae IgG/IgM Combo Rapid Test is for the qualitative detection of IgG and IgM antibodies to SARS-COV-2 and Mycoplasma pneumoniae in human whole blood, serum or plasma specimen. It is for professional use only and is intended to be used as an aid in the diagnosis of patients with suspected SARS-CoV-2/M.pneumoniae infection in conjunction with clinical presentation and the results of other laboratory tests.
INTENDED USE
The COVID-19 and M.pneumoniae IgG Combo Rapid Test (Whole Blood/ Serum/Plasma) is a lateral flow chromatographic immunoassay for the
qualitative detection of IgG antibodies to SARS-COV-2 and Mycoplasma pneumoniae in human whole blood, serum or plasma specimen.
The COVID-19 and M.pneumoniae IgG Combo Rapid Test is for professional use only and is intended to be used as an aid in the diagnosis of patients with suspected SARS-CoV-2/M.pneumoniae infection in conjunction with clinical presentation and the results of other laboratory tests. The product is intended to be used by trained laboratory personnel. Negative results will not preclude SARS-COV-2/M.pneumoniae infection and
they cannot be used as the sole basis for treatment or other management decision.
False positive results for IgG antibodies may occur due to cross-reactivity from pre-existing antibodies or other possible causes.
SPECIMEN COLLECTION AND PREPARATION
The COVID-19 and Mycoplasma pneumoniae IgG Combo Rapid Test (Whole Blood/Serum/Plasma) can be performed using whole blood (from
venipuncture or fingerstick), serum or plasma.
To collect Fingerstick Whole Blood Specimens:
Wash the patient’s hand with soap and warm water or clean with an alcohol pad. Allow to dry.
Massage the hand without touching the puncture site by rubbing down the hand towards the fingertip of the middle or ring finger.
Puncture the skin with a lancet. Wipe away the first sign of blood.
Gently rub the hand from wrist to palm to finger to form a rounded drop of blood over the puncture site.
Add the Fingerstick Whole Blood specimen to the test by using a capillary tube:
Touch the end of the capillary tube to the blood until filled to approximately 20uL. Avoid air bubbles.
Separate serum or plasma from blood as soon as possible to avoid hemolysis. Use only clear non-hemolyzed specimens.
Testing should be performed immediately after the specimens have been collected. Do not leave the specimens at room temperature for prolonged periods. Serum and plasma specimens may be stored at 2-8°C for up to 7 days, for long term storage, serum/plasma specimens should be kept below -20°C. Whole blood collected by venipuncture should be stored at 2- 8°C if the test is to be run within 2 days of collection. Do not freeze whole blood specimens. Whole blood collected by fingerstick should be tested immediately.
Bring specimens to room temperature prior to testing. Frozen specimens must be completely thawed and mixed well prior to testing. Specimens
should not be frozen and thawed repeatedly.
If specimens are to be shipped, they should be packed in compliance with local regulations covering the transportation of etiological agents.
EDTA K2, Heparin sodium, Citrate sodium and Potassium Oxalate can be used as the anticoagulant for collecting the specimen.
HOW TO USE?
Allow the test, specimen, buffer and/or controls to reach room temperature (15-30°C) prior to testing.
1.Remove the test from the foil pouch and use it within one hour. Best results will be obtained if the test is performed immediately after opening the foil pouch.
2.Place the test on a clean and level surface.
For Serum or Plasma specimen:
Transfer 10μL of serum or plasma to each of the specimen well (S) with a dropper or pipette, then add 2 drops of buffer (approximately 80 uL), and start the timer.
For Whole Blood specimen:
Transfer 20μL of whole blood to each of the sample well(S) with a dropper or pipette, then add 2 drops of buffer (approximately 80 uL), and start the timer.
3.Wait for the colored line(s) to appear. Read results at 10 minutes. Do not interpret the result after 20 minutes.
Note: It is suggested not to use the buffer, beyond 6 months after opening
Ordering Information
Cat. No.
Product
Specimen
Pack
INMC-425
COVID-19 and M.pneumoniae IgG/IgM Combo Rapid Test
WB/S/P
25 T
INMCG-425
COVID-19 and M.pneumoniae IgG Combo Rapid Test
WB/S/P
25 T
Company Details
Bronze Gleitlager
,
Bronze Sleeve Bushings
and
Graphite Plugged Bushings
from Quality China Factory
Business Type:
Manufacturer,Exporter,Trading Company
Total Annual:
80000000-100000000
Employee Number:
500~10000
Ecer Certification：
Verified Supplier
CITEST DIAGNOSTICS INC., an emerging In Vitro Diagnostics company based in Canada, is experiencing growth on a global scale, engaging in multinational operations. CITEST was founded by highly experienced IVD industry professionals with proven track records building and growing successful companies.
... CITEST DIAGNOSTICS INC., an emerging In Vitro Diagnostics company based in Canada, is experiencing growth on a global scale, engaging in multinational operations. CITEST was founded by highly experienced IVD industry professionals with proven track records building and growing successful companies.
...
